Mechelen, Belgium and Galashiels, Scotland; 27 September 2007 - Galapagos NV (Euronext & LSE: GLPG) and ProStrakan Group plc (LSE: PSK) announced today the achievement of the third milestone under Galapagos' collaboration with Novartis in antibodies for bone-related diseases. Today's milestone triggers a payment of $1.5 million to Galapagos. Galapagos will pay $1,125,000 of this amount to ProStrakan as part of their December 2006 agreement.
